.png){kind=icon}
.png){kind=icon}
Return
Letter to the Editor: AADN score predicts overall and progression-free survival in triple therapy for hepatocellular carcinoma
.png){kind=icon}
PRE
AI
L
DOI：10.3748/wjg.v32.i13.116481.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The integration of transarterial chemoembolization with immune checkpoint inhibitors and tyrosine kinase inhibitors has reshaped the therapeutic landscape of unresectable hepatocellular carcinoma. Nonetheless, outcome heterogeneity remains substantial, underscoring the need for simple and biologically grounded prognostic tools. In this recent issue of the World Journal of Gastroenterology, Zhang et al propose the AADN score, a laboratory-based model incorporating alpha-fetoprotein, alkaline phosphatase, direct bilirubin, and neutrophil-to-lymphocyte ratio. Developed using multivariable regression and validated in an independent cohort, the AADN score demonstrated good discrimination for overall and progression-free survival. This article contextualizes the score within existing prognostic systems, discusses its biological plausibility and methodological considerations, and critically appraises its current level of evidence. While the AADN score shows promise for risk stratification and hypothesis generation, further prospective and multicenter validation is required before it can inform routine clinical decision-making.
Keywords:
Hepatocellular carcinoma
Oncology
Interventional radiology
Overall survival
Liver cancer
Journal
IF:
5.4
Papers:
2.1W
Citations:
5.1W
Organization
Cited Papers